Innovative Drug

Developing Novel Antibody Biologics to Address Unmet Medical Needs

Prestige Biopharma invests its expertise and resources in the development of first-in-class antibody therapeutics to fight life-threatening diseases. To bring innovation for life, we are developing novel monoclonal and bispecific antibody drugs that that contributes to unmet medical needs.

PBP1510

PBP1710

IDC001

IDC005

: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.

IDC007

: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.

IDC008

: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.

Our groundbreaking accomplishments

Innovative Drug

Biosimliars

Pipeline

Indication

Development Stage

First-in-class

PBP1510
Ulenistamab

Pancreatic cancer, Ovarian Cancer

Clinical (Phase 1/2a)

PBP1710

Solid tumor

Preclinical

IDC111

Solid tumor

Basic Research

Bispecific Antibody

IDC001

Solid tumor

Basic Research

IDC002

Solid tumor

Basic Research

IDC003

Solid tumor

Basic Research

IDC005

Solid tumor

Discovery

IDC007

Critical immune disorders

Discovery

IDC008

Solid tumor

Discovery

IDC009

Solid tumor

Discovery

IDC010

Immune disease

Discovery

Novel Concept Antibody

IDC331

Solid tumor

Discovery

IDC332

Solid tumor

Discovery

IDC333

Solid tumor

Discovery

IDC334

Solid tumor

Discovery

Antibody Drug Conjugate

IDC441

Solid tumor

Basic Research

Diagnostic Kit

IDC221

Pancreatic cancer

Basic Research

First-in-class

PBP1510
Ulenistamab

Indication Development Stage
Pancreatic cancer, Ovarian Cancer Clinical (Phase 1/2a

PBP1710

Indication Development Stage
Solid tumor Preclinical

IDC111

Indication Development Stage
Solid tumor Basic Research

Bispecific Antibody

IDC001

Indication Development Stage
Solid tumor Basic Research

IDC002

Indication Development Stage
Solid tumor Basic Research

IDC003

Indication Development Stage
Solid tumor Basic Research

IDC005

Indication Development Stage
Solid tumor Discovery

IDC007

Indication Development Stage
Critical immune disorders Discovery

IDC008

Indication Development Stage
Solid tumor Discovery

IDC009

Indication Development Stage
Solid tumor Discovery

IDC010

Indication Development Stage
Immune disease Discovery

Novel Concept Antibody

IDC331

Indication Development Stage
Solid tumor Discovery

IDC332

Indication Development Stage
Solid tumor Discovery

IDC333

Indication Development Stage
Solid tumor Discovery

IDC334

Indication Development Stage
Solid tumor Discovery

Antibody Drug Conjugate

IDC441

Indication Development Stage
Solid tumor Basic Research

Diagnostic Kit

IDC221

Indication Development Stage
Pancreatic cancer Basic Research